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DOI 10.1016/j.ccr.2011.03.012SUMMARYAutophagy is of increasing interest as a target for cancer therapy. We find that leucine deprivation causes the
caspase-dependent apoptotic death of melanoma cells because it fails to appropriately activate autophagy.
Hyperactivation of the RAS-MEK pathway, which is common in melanoma, prevents leucine deprivation from
inhibiting mTORC1, themain repressor of autophagy under nutrient-rich conditions. In an in vivo tumor xeno-
graft model, the combination of a leucine-free diet and an autophagy inhibitor synergistically suppresses the
growth of human melanoma tumors and triggers widespread apoptosis of the cancer cells. Together, our
study represents proof of principle that anticancer effects can be obtained with a combination of autophagy
inhibition and strategies to deprive tumors of leucine.INTRODUCTION
It is not completely understood how cancer cells survive and
grow in nutrient-limiting conditions, but recent studies support
a central role for autophagy (Klionsky, 2007; Kroemer and Lev-
ine, 2008; Levine andKroemer, 2008;White et al., 2010). Autoph-
agy is a lysosome-dependent cellular degradation pathway that
is triggered by nutrient deprivation and requires the evolutionarily
conserved ATG proteins. These proteins regulate the formation
and expansion of a cup-shaped structure, termed the isolation
membrane or phagophore, which eventually encloses a portion
of cytoplasm in a double-membrane vesicle called an autopha-
gosome. In the late stages of autophagy, the outer membrane
of an autophagosome fuses with a lysosome to produce an au-
tophagolysosome, which leads to the degradation of the en-
closed cytoplasmic material by lysosomal enzymes and the re-
cycling of metabolites that cannot be synthesized de novo,
such as essential amino acids.
The development of the isolation membrane has two major
steps: nucleation and elongation. The nucleation step requiresSignificance
Melanoma is a highly aggressive cancer for which additional t
nism that may help cancer cells survive in nutrient-limiting co
However, in preclinical tumor models inhibition of autophagy
Here, we show that the combination of leucine deprivation and
in vitro and in vivo, of human melanoma cells driven by the RAS
represent a starting point for developing combination therapiethe ATG1/ULK1 kinase and the type III phosphoinositide
3-kinase (PIK3C3)/VPS34 kinase complex, and the elongation
step the ATG8/LC3- and ATG12-conjugation systems (Levine
and Kroemer, 2008; Nakatogawa et al., 2009). A key regulator
of the nucleation of the isolation membrane is the mTOR
complex 1 (mTORC1) signaling pathway. Under nutrient-rich
conditions, mTORC1 suppresses autophagy by inhibiting, in
a poorly understood fashion, the ATG1/ULK1 kinase complex
(Hosokawa et al., 2009; Jung et al., 2009). ThemTORC1 pathway
is sensitive to amino acid levels (Hara et al., 1998), and amino
acid deprivation activates autophagy (Mortimore and Schworer,
1977; Schworer et al., 1981). How amino acids activatemTORC1
is not well understood, but recent work has revealed an essential
role for the amino acid-stimulated translocation of mTORC1 to
the lysosomal surface (Sancak et al., 2008; Sancak et al., 2010).
Cells can differ in which amino acids they require for survival,
and oncogenic transformation may make them liable to the defi-
ciency of a particular amino acid. For example, human fibro-
blasts with activated c-MYC depend on glutamine (Yuneva
et al., 2007), lymphoblastic leukemia cells require tryptophan,herapies are needed. Autophagy is a cytoprotective mecha-
nditions and is a potential target for anticancer therapies.
alone has so far had relatively modest antitumor effects.
autophagy inhibition induces the caspase-dependent death,
-MEK pathway, but not of nontransformed cells. The results
s involving autophagy inhibitors to target melanoma.
Cancer Cell 19, 613–628, May 17, 2011 ª2011 Elsevier Inc. 613
H
EK
-2
93
T
Caspase-3
Cleaved 
Caspase-3
A-
20
58
Caspase-3
Cleaved 
Caspase-3
Protein mass Apoptosis Protein mass Apoptosis
Protein mass Apoptosis
0
20
40
60
80
100
120
0
20
40
60
80
100
0
20
40
60
80
100
120
0
20
40
60
80
100
Pr
ot
ei
n 
m
as
s 
(%
 O
D6
00
)
Pr
ot
ei
n 
m
as
s 
(%
 O
D6
00
)
 
 
 
 
 
 
 Apoptosis
(% c.caspase-3)
C F
Ct
rl
Ad
rH I K L M Q R T V W Y
C FCt
rl
Ad
r
H I K L M Q R T V W Y
 
 
 
 
 
 Apoptosis
(% c.caspase-3)
C F
Ct
rl
Ad
rH I K L M Q R T V W Y
M
el
-S
TM
K
Caspase-3
Cleaved 
Caspase-3
M
el
-S
TR
Caspase-3
Cleaved 
Caspase-3
M
el
-S
T
Caspase-3
Cleaved 
Caspase-3
 
 
 
 
 
 Apoptosis
(% c.caspase-3)
 
 
 
 
 
 Apoptosis
(% c.caspase-3)
 
 
 
 
 
 Apoptosis
(% c.caspase-3)
C FCt
rl
Ad
r
H I K L M Q R T V W Y
C FCt
rl
Ad
r
H I K L M Q R T V W Y
C FCt
rl
Ad
r
H I K L M Q R T V W Y
C FCt
rl
Ad
r
H I K L M Q R T V W Y
0
20
40
60
80
100
120
0
20
40
60
80
100
0
20
40
60
80
100
120
0
20
40
60
80
100
0
20
40
60
80
100
120
0
20
40
60
80
100
C F
Ct
rl
Ad
rH I K L M Q R T V W Y
C F
Ct
rl
Ad
rH I K L M Q R T V W Y
Pr
ot
ei
n 
m
as
s 
(%
 O
D6
00
)
 
 
 
 
 
 Apoptosis
(% c.caspase-3)
 
 
 
 
 
 Apoptosis
(% c.caspase-3)SK
-M
EL
-5
Caspase-3
Cleaved 
Caspase-3
SK
-M
EL
-3
Caspase-3
Cleaved 
Caspase-3
SK
-M
EL
-2
8
Caspase-3
Cleaved 
Caspase-3
C FCt
rl
Ad
r
H I K L M Q R T V W Y
C F
Ct
rl
Ad
rH I K L M Q R T V W Y
0
20
40
60
80
100
120
0
20
40
60
80
100
0
20
40
60
80
100
120
0
20
40
60
80
100
0
20
40
60
80
100
120
0
20
40
60
80
100
 
 
 
 
 
 Apoptosis
(% c.caspase-3)
C F
Ct
rl
Ad
rH I K L M Q R T V W Y
C FCt
rl
Ad
r
H I K L M Q R T V W Y
C FCt
rl
Ad
r
H I K L M Q R T V W Y
A-
20
58
SK
-M
EL
-5
6
A B
D
E
C
C F
Ct
rl
Ad
rH I K L M Q R T V W Y
C F
Ct
rl
Ad
rH I K L M Q R T V W Y
Pr
ot
ei
n 
m
as
s 
(%
 O
D6
00
)
Pr
ot
ei
n 
m
as
s 
(%
 O
D6
00
)
Pr
ot
ei
n 
m
as
s 
(%
 O
D6
00
)
Pr
ot
ei
n 
m
as
s 
(%
 O
D6
00
)
Pr
ot
ei
n 
m
as
s 
(%
 O
D6
00
)
M
el
-S
T
M
el
-S
TM
K
C
el
l n
um
be
r (
x1
0  
)6
Annexin-V-Fluorescein
- Leucine
A-
20
58
M
el
-S
TM
K
1 2 3 4
0
1
2
3
4
 Control media
- EAA
- Ile
- Leu
1 2 3 4
0
1
2
3
4
 Control media
- EAA
- Ile
- Leu
1 2 3 4
0
1
2
3
4 Control media
- His
- Ile
- Leu
- EAA
1 2 3 4
0
1
2
3
4 Control media
- His
- Ile
- Leu
- EAA
C
el
l n
um
be
r (
x1
0  
)6
Days
C
el
l n
um
be
r (
x1
0  
)
C
el
l n
um
be
r (
x1
0  
)
6
Days
Days Days
Pr
op
id
iu
m
 io
di
de
Day 0 Day 1 Day 2 Day 3
0.104
0.026*
0.001
0.051
0.001
*
*
< 0.001
< 0.001
*
*
*
0.036
0.008
*
*
0.009
Figure 1. Leucine Deprivation Induces Apoptosis in Human Melanoma Cells
(A–C) Survey of patient-derivedmelanoma cells (A), immortalized humanmelanocytes and the nonmelanocyte-derived line (B), and transformedmelanocytes (C).
Immunoblot analyses for intact and cleaved caspase-3 of indicated cell lines following a 48-hr deprivation for individual essential amino acids. Bar graphs indicate
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Leucine Deprivation Triggers Melanoma Apoptosismethionine, and valine (Gong et al., 2000; Kreis et al., 1980; Oh-
tawa et al., 1998; Woolley et al., 1974), and several types of solid
tumor cells require arginine (Scott et al., 2000). However, in most
cases the cellular underpinnings behind the particular amino
acid requirements of a cancer cell type are largely unknown,
making it difficult to exploit such information to implement anti-
cancer therapeutics. Here, we investigated which essential
amino acids are necessary for the survival of human melanoma
cells and identified an oncogenic-signaling pathway that deter-
mines their sensitivity to leucine deprivation.RESULTS
Leucine Deprivation Triggers the Apoptotic Cell Death
of Human Melanoma Cells
We examined the survival of four patient-derived melanoma cell
lines (A-2058, SK-MEL-3, SK-MEL-5, SK-MEL-28) as well as the
nontransformed but immortalized human Mel-ST melanocyte
line (Figures 1A and 1B). We used the cleavage of caspase-3
as a readout for the caspase-dependent apoptosis (Galluzzi
et al., 2009; Kroemer et al., 2009; Taylor et al., 2008). Cas-
pase-3 cleaves an array of apoptosis-related proteins, including
PARP (see Figure S1A available online).
Cells were deprived, one amino acid at a time, of the 13 amino
acids that are considered universally (F, I, K, L, M, T, V, W) or
conditionally (C, H, Q, R, Y) essential in humans (Berg et al.,
2007; Eagle, 1959). We deprived the melanoma cells of only
essential amino acids because the cell lines could have differing
capacities to synthesize nonessential amino acids, which would
greatly confound the interpretation of the results. Unsurprisingly,
upon the deprivation of any single essential amino acid, all cell
lines halted proliferating and had a concomitant decrease in
cyclinD1 levelsandproteinmass (Figures1Aand1B;FigureS1A).
In contrast themelanoma cell lines differed inwhich particular set
of amino acids, when individually omitted from the media, trigger
the cleavage of caspase-3 (Figure 1A). Interestingly, in all the
melanoma lines, the only constant was that leucine deprivation
triggered cleavage of caspase-3 and the corresponding cas-
pase-dependent cleavage of PARP (Figure S1A). However,
leucine deprivation did not induce caspase-3 cleavage in non-
transformed Mel-ST melanocytes or nonmelanocyte-derived
HEK293Tcells (Figure1B). TheDNA-damagingagentAdriamycin
did induce caspase-3 cleavage in these latter two lines, like in the
patient-derived melanoma cells (Figures 1A and 1B).
Consistent with the caspase-3 cleavage results, an Annexin-V
assay (Galluzzi et al., 2009; Kroemer et al., 2009) revealed, upon
leucine deprivation, a time-dependent increase in phosphatidyl-
serine (PS) on the outer leaflet of the plasma membrane of
A-2058 cells (Figure 1D). The increase in Annexin-V staining
preceded the eventual loss of plasmamembrane integrity, whichrelative changes in protein mass (a readout for cell growth and proliferation) and pe
lines indicate 10% activation of caspase-3. Ctrl, control RPMI-1640 media; C-F-H
letter code for amino acid); Adr, Adriamycin at 2 mg/ml.
(D) Annexin-V assay for apoptosis induction. FL1; Annexin-V-Fluorescein, FL2; P
(E) Cell survival assay. Cells were deprived of all essential amino acids (EAA), h
control RPMI-1640 media, and changes in cell number were measured at indica
values that are significantly different from controls.
See also Figure S1.was detected by an increase in propidium iodide staining at the
later time points (Figure 1D).
Hyperactivation of the RAS-MEK Pathway Renders
Melanocytes Dependent on Leucine for Survival
Because all the melanoma lines in our study have activating
mutations in the RAS-MAPK pathway (COSMIC database, Well-
come Trust Sanger Institute) (Bamford et al., 2004), we asked if
Ras pathway hyperactivation could confer on melanocytes the
capacity to induce caspase-3 activation upon leucine depriva-
tion. Indeed, Mel-STR cells, an engineered melanoma line
generated by transforming Mel-ST melanocyte with oncogenic
RAS-G12V (Gupta et al., 2005), very strongly induced caspase-
3 cleavage when deprived of leucine (Figure 1C). Mel-STMK
cells, which are Mel-ST cells expressing an activated allele of
MEK1 (MEK1-Q56P) (Bottorff et al., 1995; Marks et al., 2008),
behaved very similarly to Mel-STR cells in the caspase-3
cleavage assay and to A-2058 cells in the Annexin-V assay
(Figures 1C and 1D). These data support the notion that the
RAS-MEK pathway is responsible for the sensitivity of melano-
cytes to leucine deprivation. Consistent with this interpretation,
U-0126 (a small molecule inhibitor of MEK1/2) (Davies et al.,
2000; Favata et al., 1998), but not KT5720 (an inhibitor of PKA),
prevented the cleavage of caspase-3 in Mel-STR cells deprived
of leucine (Figure S1B).
Of the several components of the RAS-MAPK pathway found
mutated in human cancers, BRAF is a critical oncogene in mela-
noma. Of disease cases, 50%–70% have activating mutations in
it (Garnett and Marais, 2004; Gray-Schopfer et al., 2007), and all
the patient-derived melanoma lines in our survey carry a mutant
allele of BRAF (Bamford et al., 2004). Therefore, we asked if
expression of oncogenic BRAF-V600E, the most common
BRAF mutant allele found in melanoma (Davies et al., 2002),
mimics the effects of RAS-G12V and MEK1-Q56P in sensitizing
melanocytes to apoptosis upon leucine deprivation. Indeed,
expression ofBRAF-V600E aswell asBRAF-D3-V600E, a variant
that cannot interact with CRAF (Karreth et al., 2009), promoted
the cleavage of caspase-3 upon leucine withdrawal (Figure S1C).
Expression of wild-type BRAF or the BRAF-D3 variant without
the V600E mutation did not have the same effects (Figure S1C).
Together, these results support a key role for the RAS-BRAF-
MEK1 signaling axis in determining the liability of the cells to
leucine deprivation.
We also determined the capacity of cells to resume prolifera-
tion upon reseeding equal number of cells at 80% cell conflu-
ency into complete media after being deprived of leucine, isoleu-
cine, or all amino acids. Mel-STMK, A-2058, and SK-MEL-5, but
not Mel-ST, cells deprived of leucine failed to show proliferation
when reseeded (Figure 1E). Just changing the media into
complete media without reseeding also showed concordant
results with those in which cells were reseeded, which excludesrcent activation of caspase-3 (ratio of cleaved to full-length caspase-3). Dotted
-I-K-L-M-Q-R-T-V-W-Y, deprivation of the indicated single amino acid (single-
ropidium Iodide, UR; upper-right quadrant, LR; lower-right quadrant.
istidine (His), isoleucine (Ile), or leucine (Leu) for 2 days and reseeded into
ted time points. Data are represented as mean ± SD, and asterisk (*) indicates
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Figure 2. Activation of Caspase Cascade through theMitochondrial Apoptotic Pathway Is Necessary for Leucine Deprivation-Induced Death
(A) Micrographs showing morphological changes following deprivations of all essential amino acids (EAA), isoleucine, or leucine in the presence or absence of
20 mM Q-VD-OPH. Scale bar, 100 mm.
(B) Immunoblot analyses showing the dose-dependent inhibitory effect of increasing concentrations of Q-VD-OPH (0, 5, 20, and 100 mM) on caspase-mediated
processes.
(C) Cell survival assay. Cells were deprived of leucine (Leu) for 2 days in the presence or absence of pan-caspase inhibitors, 20 mM Q-VD-OPH, or 100 mM
Z-VAD-fmk.
(D) Flow cytometric analyses showing changes in MOMP using JC-1 dye. FL1, green fluorescence of J-monomer; FL2, red fluorescence of J-aggregates.
(E) Immunoblot analyses show the effect of Bcl-xL expression on caspase-3 activation upon leucine deprivation.
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results observed (Figure S1D). In contrast to the results observed
with leucine deprivation, all cell lines deprived of isoleucine or all
essential amino acids successfully resumed proliferation (Fig-
ure 1E). In SK-MEL-5 and A-2058 cells deprived of histidine,
the extent of cell survival inversely correlated with that of cas-
pase-3 cleavage (Figures 1A and 1E).
Caspase Activity Regulated by the Mitochondrial
Apoptotic Pathway Is Necessary for Cell Death Caused
by Leucine Deprivation
To investigate if the apoptotic caspases are required for leucine
deprivation to trigger cell death, we used the pan-caspase inhib-
itors Q-VD-OPH (Caserta et al., 2003; Chauvier et al., 2007) and
Z-VAD-fmk (Slee et al., 1996). Q-VD-OPH inhibits a spectrum of
caspases with high specificity, whereas Z-VAD-fmk may also
inhibit other types of proteases, including calpains and lyso-
somal cathepsins (Caserta et al., 2003; Chauvier et al., 2007;
Kroemer et al., 2009). Q-VD-OPH inhibited the morphological
changes characteristic of apoptosing cells, as well the cas-
pase-dependent cleavage of PARP in cells deprived of leucine
(Figures 2A and 2B). Critically, Q-VD-OPH and Z-VAD-fmk
greatly increased the survival of melanoma cells deprived of
leucine (Figure 2C). Because Q-VD-OPH did not completely
rescue cells from cell death induced by leucine deprivation, it
is possible that othermechanisms in addition to caspase-depen-
dent apoptosis may also contribute to the death of the cells.
The caspase inhibitor experiments also hinted at how leucine
deprivation activates the caspase cascade. Not only did Q-VD-
OPH inhibit the cleavage of PARP, a known substrate of cas-
pase-3, but also the self-cleavage at Asp-315 of caspase-9. As
an initiator caspase of the mitochondrial pathway, caspase-9
regulates executioner caspases, including caspase-3 (Fig-
ure 2B). Consistent with this finding, leucine deprivation
increased the mitochondrial outer membrane permeabilization
(MOMP) of A-2058 andMel-STMK, but notMel-ST, cells (Figures
2D and 2F). To determine if the increase in MOMP is necessary
for the cell death caused by leucine deprivation, we established
A-2058 cells overexpressing Bcl-xL (Figure 2E). In contrast to the
parental line, Bcl-xL-overexpressing cells did not increase
MOMP or trigger cleavage of caspase-3 when deprived of
leucine (Figures 2E and 2F). The decrease in caspase-3 activa-
tion in Bcl-xL-overexpressing cells under no leucine conditions
directly correlated with an increase in their survival (Figure 2G).
These results support an important role for the mitochondrial
apoptotic pathway in triggering cell death upon leucine
deprivation.
Leucine Deprivation Does Not Activate Autophagy
in Melanocyte-Derived Cells with Constitutively Active
RAS-MEK Signaling
To investigate why the deprivation of leucine, but not other
essential amino acids, is a universal inducer of apoptosis in
melanoma cells, we examined the effects of leucine deprivation
and RAS signaling on autophagy activity. It is increasingly appre-
ciated that autophagy is critical for cells to survive nutrient depri-(F) Flow cytometric analyses showing changes in MOMP.
(G) Cell survival assay. Data are represented as mean ± SD, and asterisk (*) indicvation and that amino acids are major regulators of this process
(Klionsky, 2007; Levine and Kroemer, 2008).
We used a fluorescent protein-tagged LC3 reporter to quanti-
tate autophagy activity. This dual-color DsRed-LC3-GFP
reporter is a modified form of the classical GFP-tagged LC3
reporter (Kabeya et al., 2000), and provides two readouts for au-
tophagy activity: the number of DsRed-LC3 puncta, and a flow
cytometric measurement we call the autophagy index. Like
previous results obtained using a GFP-LC3 reporter (Kabeya
et al., 2000), our reporter showed an increase in the number of
DsRed-LC3 puncta upon a phosphate-buffered saline (PBS)
incubation or amino acid deprivation (Figure 3). The reporter
has GFP separated from the C terminus of LC3 by a recognition
site for the autophagic protease, ATG4, and loss of GFP fluores-
cence can be monitored by flow cytometry (see Figure S2 for
details). As expected, deletion of the ATG4 recognition
sequence abrogated the sensitivity of the reporter to low nutrient
conditions (Figures S2C–S2E). In comparison to the control
media condition, deprivation of all amino acids significantly
decreased the levels of the full-length DsRed-LC3-GFP reporter
as detected by immunoblotting (Figure S2B). To represent
results obtained by flow cytometry, we introduced an autophagy
index, which normalizes the change in GFP fluorescence to that
in DsRed-LC3 fluorescence (see Experimental Procedures and
Figure S2). With the autophagy index, potential changes in the
synthesis of the reporter following amino acid deprivations can
be normalized. Importantly, our autophagy index tightly corre-
lated with the number of DsRed-LC3 puncta, an established
measure of autophagy (Figures 3A–3D; Figure S2).
Mel-ST cells displayed a steady-state level of autophagic
activity, with an40% autophagy index when growing in control
media. As expected, the autophagy index increased (to 70%–
80%) following deprivation of all amino acids or most single
amino acids. In contrast, leucine deprivation failed to signifi-
cantly activate autophagy (Figures 3A–3C). Immunoblot anal-
yses also showed that deprivation of just leucine did not reduce
the level of the full-length DsRed-LC3-GFP reporter, whereas
deprivation of all amino acids or just isoleucine did (Figure S2B),
indicating a defect in the regulation of autophagy upon leucine
deprivation. This difference is unlikely due to a change in protea-
somal activity because deprivation of all amino acids, isoleucine,
or leucine equally affected the levels of Cyclin D1, a short-lived
protein whose turnover is regulated by the ubiquitin-proteasome
pathway (Figures S1A and S2B) (Alao, 2007; Diehl et al., 1997). In
HEK293T cells the capacity of leucine deprivation to induce au-
tophagy was indistinguishable from that of isoleucine, methio-
nine, or all amino acids (Figure 3D). Thus, in a melanocyte-
derived cell line, leucine is exceptional among the amino acids
in that its deprivation does not activate autophagy.
It also quickly became apparent that, compared to the
parental Mel-ST cells, the Mel-STR and Mel-STMK cells have
a significant defect in autophagy upon nutrient withdrawal
(Figures 3E and 3F). In these engineered melanoma cells, PBS
incubation, complete amino acid deprivation, and isoleucine
deprivation activated autophagy to smaller degrees than the
same treatments did in parental Mel-ST cells (Figures 3E andates values that are significantly different from controls.
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Figure 3. Deprivation of Leucine Does Not Activate Autophagy in Melanoma Cells with Activated Ras-MEK Signaling
(A) Fluorescent micrographs showing autophagy markers. Control, complete RPMI-1640 media control; EAA, deprivation of all essential amino acids, Ile,
deprivation of isoleucine; Leu, deprivation of leucine. DAPI, cell nuclei; DsRed-LC3, red fluorescence from DsRed-LC3 puncta; GFP, green fluorescence from
the uncleaved DsRed-LC3-GFP reporter; Merge, merged image of DAPI, DsRed, and GFP signals.
(B) Quantitation of DsRed-LC3 puncta. Bar graphs display themean ± SD of DsRed-LC3 puncta per cell following each type of nutrient starvation. The numbers of
cells examined are indicated.
(C) Flow cytometric analyses of autophagic activity. The bar graphs show mean ± SD of autophagy indexes obtained after deprivation of single essential amino
acids for 24 or 48 hr (n = 3). Dotted lines indicate the autophagy index of cells incubated in control media.
(D) Autophagy index in HEK293T cells following PBS incubation or indicated amino acid deprivations.
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Leucine Deprivation Triggers Melanoma Apoptosis3F). Importantly, upon leucine deprivation, autophagy levels
were evenmore greatly suppressed in the engineeredmelanoma
cells, indicating that leucine deprivation has a profound impact
on autophagy in the melanocyte-derived lines with activated
RAS-MEK signaling (Figures 3E and 3F).
Constitutive Activation of MEK Renders the mTORC1
Pathway Resistant to Leucine Deprivation
Because mTORC1 suppresses autophagy (Kamada et al., 2000;
Noda and Ohsumi, 1998) and amino acids activate mTORC1
(Hara et al., 1998), we asked if inappropriate regulation of
mTORC1 might explain why leucine deprivation does not stimu-
late autophagy in cells with activated RAS-MEK signaling. We
monitored mTORC1 activity by measuring the phosphorylation
of S6K1 at Thr-389, a site that mTORC1 directly phosphorylates
(Burnett et al., 1998). In the same cells we also monitored au-
tophagy activity by examining endogenous LC3-I to LC3-II
conversion and the eventual degradation of LC3 (Figure 4A).
Deprivation of all amino acids acutely suppressed mTORC1
and activated autophagy in Mel-ST cells. Mel-STMK cells
behaved similarly except that these cells maintained some
residual mTORC1 activity, even after a long period of essential
amino acid deprivation (Figure 4A). However, the more inter-
esting findings were obtained upon leucine deprivation. In
contrast to all amino acid deprivation, leucine deprivation was
a much poorer inhibitor of mTORC1 and, consequently, inducer
of autophagy (Figure 4A). Strikingly, in Mel-STMK cells, leucine
deprivation barely inhibited mTORC1 activity. Consistent with
the results obtained with the autophagy reporter, leucine depri-
vation did not cause substantial LC3-I to LC3-II conversion or
loss of endogenous LC3 in Mel-STMK cells (Figure 4A).
To further investigate why leucine deprivation fails to suppress
mTORC1 signaling in cells that have constitutively active MEK,
we examined the amino acid-sensitive translocation of mTORC1
to the lysosomal surface (Figures 4B; see Figure S3 for high-
resolution images and quantitation). Recent work indicates that
the key event in amino acid signaling to mTORC1 is the amino
acid-induced movement of mTORC1 to lysosomal membranes,
where it can interact with its activator, Rheb, a small GTPase
(Sancak et al., 2010). Constitutive targeting of mTORC1 to the
lysosomal surface is sufficient to render the mTORC1 pathway
insensitive to amino acid levels (Sancak et al., 2010). As ex-
pected, mTORC1 did not colocalize with the lysosomal marker
LAMP2 in Mel-ST and Mel-STMK cells deprived of all amino
acids for 50 min (Figure 4B). In contrast, in both lines the depri-
vation of just leucine for 50 min did not greatly affect the coloc-
alization of mTORC1 with lysosomes. However, after depriving
the cells of leucine for a longer period of time (4 hr), the two lines
diverged in their behavior: in Mel-ST cells, mTORC1 no longer
colocalized with lysosomes, whereas in Mel-STMK cells
mTORC1 remained lysosome associated (Figure 4B). These
findings are consistent with the RAS-MEK pathway impacting
mTORC1 upstream of the leucine-sensitive machinery that regu-
lates the subcellular localization of mTORC1.(E) Flow cytometric quantitation of the autophagy activity. ‘‘m’’ marks line indicatin
media.
(F) Bar graphs show mean ± SD of the autophagy index (n = 3), and asterisk (*) i
See also Figure S2.Inappropriate Activation of the mTORC1 and RAS-MEK
PathwaysConfers Sensitivity to Apoptosis upon Leucine
Deprivation
To determine if the failure to suppress the mTORC1 pathway in
melanoma cells with activated RAS-MEK signaling causes cell
death, we examined the effects of small molecule inhibitors of
the signaling pathways. Mel-STR cells treated with rapamycin
or U-0126 not only reactivated autophagy (Figure 5A) but also
suppressed caspase-3 activation (Figure 5B). Moreover, across
several patient-derived melanoma lines, rapamycin and U-0126
were equally effective at suppressing the cleavage of caspase-3
caused by leucine deprivation (Figures 5C–5E). Importantly, the
mTORC1 or MEK inhibitor significantly increased the survival of
leucine-deprived melanoma cells (Figures 5F–5H).
Autophagy Inhibition Mimics Activated RAS-MEK
Signaling in Conferring Sensitivity to Leucine
Deprivation
Upon leucine deprivation, autophagy ismore strongly inhibited in
Mel-STR than Mel-ST cells (Figures 3E and 3F). To determine if
this difference is sufficient to confer on Mel-STR cells the
capacity to trigger caspase-3 cleavage upon leucine withdrawal,
we asked if the suppression of autophagy sensitizes, like RAS-
MEK pathway activation, Mel-ST cells to leucine deprivation.
To inhibit autophagywe employed two distinct shRNAs targeting
ATG1 (autophagy related gene 1, also known as ULK1) that
greatly reduce ATG1 protein expression (Figure 5I). ATG1 is an
evolutionarily conserved, Ser/Thr protein kinase that plays an
essential role in the early stages of autophagy (Chan et al.,
2007; Matsuura et al., 1997). Indeed, the knockdown of ATG1
was as effective as the expression of Ras-G12V or MEK1-
Q56P in sensitizing Mel-ST cells to leucine deprivation (Fig-
ure 5J). Similar results were obtained by knocking down
VPS34, the class III PI3K (Figure S4A). These results confirm
that a particular level of autophagy is necessary for cells to
survive essential amino acid deprivation, and suggest that,
when deprived of leucine, melanoma cells with activated RAS-
MEK fall below this threshold.
A Small Molecule Inhibitor of Autophagy Sensitizes
Melanoma Cells to Partial Leucine Deprivation In Vitro
To explore the potential therapeutic implications of the finding
that melanoma cells die upon complete leucine deprivation, we
needed to identify a way to sensitize melanoma cells to partial
leucine deprivation because, to our knowledge, it is currently
not possible to completely deprive, in vivo, cancer cells of extra-
cellular leucine. Because all cells have a basal level of autophagy
that likely contributes to the recycling of essential amino acids,
we reasoned that if we partially suppressed autophagy with
a small molecule inhibitor, the melanoma cells might induce
apoptosis even if some leucine remained in the extracellular
environment.
The feasibility of this idea was investigated using chloroquine,
a small molecule inhibitor of autophagy. Chloroquine isgmedian fluorescence intensity of FL1 (GFP fluorescence) in cells in the control
ndicates values that are significantly different from controls.
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Figure 4. Deregulated Activation of the mTORC1 Pathway by Constitutively Active MEK Correlates with the Inappropriate Localization of
mTOR to the Lysosomal Surface
(A) Immunoblot analyses showing time-dependent changes inmTORC1 and autophagy activity in indicated cell types following deprivation for all essential amino
acids or leucine.
(B) Immunofluorescence analyses showing mTOR localization upon the deprivation of all essential amino acids (EAA) or leucine (Leu). Cells were deprived of
indicated amino acids for short (50min) or long (4 hr) periods of time, and refed with the amino acids for 10min before processing for coimmunostaining for mTOR
(red) and LAMP2 (green), and imaging. In all images, insets show selected fields that were magnified five times and their overlay. Scale bar, 10 mm.
See also Figure S3.
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Leucine Deprivation Triggers Melanoma Apoptosisa lysosomotropic drug that inhibits the late stages of the autoph-
agy pathway (Boya et al., 2005) and is currently in many clinical
trials as an anticancer agent (http://www.clinicaltrials.gov). As
expected, in A-2058 cells, chloroquine increased the levels of
p62/SQSTM1/Sequestosome-1 and prevented loss of LC3-II
(Figure S5A). By directly binding to LC3, p62 is incorporated
onto autophagosomes and degraded (Bjorkoy et al., 2005) so
that the level of p62 inversely correlates with autophagic activity
(Mizushima et al., 2010).
To answer if chloroquine can induce apoptosis of melanoma
cells upon a partial depletion of leucine, we first determined
the greatest concentration of extracellular leucine that is still
low enough to trigger apoptosis of the melanoma cells in culture
(Figures 5K and 5L). We examined a range of leucine concentra-
tions: 380 mM (the concentration of leucine in RPMI media);
120 mM (approximately the plasma leucine concentration of
mice fed a normal diet); and 60 mM (approximately the plasma
leucine concentration of mice fed an isocaloric, leucine-free
synthetic diet; Anthony et al. [2004]). In the absence of chloro-
quine, only an extracellular leucine concentration of 30 mM or
below was able to activate caspase-3 cleavage (Figures 5K
and 5L). In contrast, when also treated with a moderate amount
of chloroquine, A-2058 and Mel-STR cells triggered caspase-3
activation, even when cultured in media containing 60 mM
leucine (Figures 5K and 5L). When completely deprived of
leucine and treated with chloroquine, Mel-ST cells did cleave
some caspase-3 (Figures 5K), consistent with the results ob-
tained upon the knockdowns of ATG1 and VPS34 (Figures 5J;
Figure S4A). Interestingly, the combination of chloroquine treat-
ment with the deprivation of all amino acids or just methionine
also promoted apoptosis, albeit to a smaller extent than that
caused by chloroquine and leucine deprivation (Figure S4B).
Most importantly, the combination of media containing 60 mM
leucine and chloroquine synergistically decreased the survival
of A-2058 cells (Figure 5M). Collectively, these results demon-
strate that chloroquine-mediated suppression of autophagy
sensitizes melanoma cells to the levels of plasma leucine that
can be achieved by feeding animals a leucine-deficient diet (An-
thony et al., 2004).
Dietary Leucine Deprivation and Autophagy Inhibition
Synergistically Target Melanoma Xenografts In Vivo
To assess the potential of the combination strategy in vivo,
A-2058 cells were injected subcutaneously into immunocompro-
mised mice to establish tumor xenografts. When the tumors
were 100 mm3 in volume, the host animals were fed: (1)
a control diet, which consisted of a leucine-free diet supple-
mented with leucine; (2) an isocaloric leucine-free diet; (3) the
control diet and treated with chloroquine; or (4) the leucine-free
diet and treated with chloroquine (Figure 6). The amount of chlo-
roquine used was 60 mg/kg body weight, which is similar to the
dose employed by others (Amaravadi et al., 2007), and that in our
hands caused no obvious toxicity to the animal. Chloroquine
treatment did inhibit autophagy in vivo because an immunohisto-
chemical assay revealed the expected increase in p62 levels in
the tumors of chloroquine-treated mice (Figure S5B).
On its own, dietary leucine deprivation did not significantly
affect tumor size. In contrast the tumors in the mice treated
with a combination of dietary leucine deprivation and chloro-quine were significantly smaller than those in mice in the control
groups (Figures 6A and 6B). The inability of a leucine-free diet to
reduce tumor growth on its own likely reflects the fact that
a leucine-free diet decreases plasma leucine levels from 133
to 76 mM (Anthony et al., 2004), which our in vitro results
show is not low enough on its own to induce significant death
of melanoma cells (Figures 5L and 5M).
To determine if the synergistic effects on tumor size of dietary
leucine deprivation and chloroquine treatment reflect the
increased death of the melanoma cells, we stained the tumor
sections with an in situ TUNEL assay (Figures 6C–6E). Analogous
to the results in culture (Figures 5L and 5M), the combination
treatment had a strong pro-death effect in vivo, so that extensive
TUNEL-positive staining was observed in nearly all areas of the
tumors (Figure 6C). Only cells in the outer shell of the tumors
and in the immediate vicinity to the microcapillaries appeared
to be spared (Figures 6D and 6E). This pattern of survival likely
reflects that melanoma cells in cuffs surrounding the tumor
vessels have access to greater amounts of leucine than cells
farther away from the blood supply. Dietary leucine deprivation
alone showed a significant, but less effective, induction of death
of the melanoma cells in vivo, and chloroquine treatment alone
promoted the death of the cells in only a few isolated areas of
the tumor (Figures 6C and 6D).
Immunohistochemical analyses of the tumors with a site-
specific (D175) cleaved caspase-3 antibody revealed that, like
in vitro, partial leucine deprivation in combination with chloro-
quine treatment caused caspase-3 cleavage in vivo (Figures
7A and 7B). The cleaved caspase-3 signal was highest at the
border between the viable cuffs surrounding capillaries and the
large areas of strongly TUNEL-positive dead cells (Figure 7B).
This pattern suggests that caspases likely initiate cell death,
but as the apoptotic program progresses, the amount of cleaved
caspase-3 drops, whereas the DNA fragments in the apoptotic
bodies persist.
Most of the live cells within the tumors stained for the human-
specific melanocyte marker, Melan-A, except for the murine
endothelial cells of the capillaries and a thin layer of cells on
the tumor surfaces (Figures 7A; Figure S5C). These Melan-A-
negative murine cells did not stain for cleaved caspase-3, indi-
cating that the combination of dietary leucine deprivation and
chloroquine treatment did not affect the nontransformed cells
of the tumors (Figure S5C).
DISCUSSION
There is mounting interest in the roles nutrient-sensing and
metabolic pathways play in tumorigenesis and in the potential
of these pathways to harbor targets for cancer therapies.
Autophagy, for example, is increasingly recognized as important
for eukaryotic cells and organisms to survive periods of nutrient
withdrawal (Boya et al., 2005; Degenhardt et al., 2006; Kuma
et al., 2004), and small molecule inhibitors of autophagy, such
as chloroquine, are of interest for anticancer uses (reviewed in
Rubinsztein et al., 2007).
In examining how cancer cells respond to deprivation of single
essential amino acids, we made the observation that the depri-
vation of leucine, but not other essential amino acids, induces
apoptosis in all the human melanoma lines studied. SubstantialCancer Cell 19, 613–628, May 17, 2011 ª2011 Elsevier Inc. 621
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Figure 5. The Inhibition of Autophagy Synergizes with Low Leucine Concentrations in Inducing Apoptosis in Melanoma Cells
(A) Bar graphs displaying the autophagy index in the presence or absence of rapamycin (RAPA) or U-0126.
(B–E) Immunoblot analyses for cleavage and activation of caspase-3 and cleavage of PARP.
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Leucine Deprivation Triggers Melanoma Apoptosisevidence suggests that leucine deprivation triggers apoptosis
because, unlike in other cell types, it does not inhibit the
mTORC1 pathway and, thus, does not activate autophagy. In
fact the mTORC1 inhibitor rapamycin—normally thought of as
an anticancer agent—reactivates autophagy in leucine-deprived
melanoma cells and promotes their survival. It is odd that the
mTORC1 pathway is so resistant to leucine withdrawal in mela-
noma cells because this amino acid is a canonical activator of
the pathway, and its deprivation inhibits mTORC1 signaling in
a wide variety of normal and transformed cells (Guertin and Sa-
batini, 2007). Amino acid signaling to mTORC1 is a subject of
intense study, but the amino acid-sensing mechanism remains
a mystery. It is possible that once the mechanism is understood,
it will be found to be different in melanoma cells than in other cell
types. The hyperactivation of the RAS-MAPK pathway that is
a common occurrence in melanoma cells clearly contributes to
the insensitivity of mTORC1 to leucine deprivation. So far, our
work suggests that RAS-MEK signaling perturbs the normally
leucine-sensitive localization of mTORC1 to the lysosomal
surface. Kinases that are part of the MAPK pathway, such ERK
and p90 RSK1, phosphorylate and repress the function of
TSC2, a tumor suppressor that is a negative regulator of
mTORC1 (Inoki et al., 2003; Ma et al., 2005; Roux et al., 2004;
Tee et al., 2003). However, TSC2 does not appear to play amajor
role in amino acid signaling to mTORC1 (Byfield et al., 2005;
Nobukuni et al., 2005; Smith et al., 2005), so it is likely that the
MAPK pathway affects the leucine sensitivity of mTORC1 in
melanoma cells through TSC2-independent mechanisms. Inter-
estingly, the RAS pathway negatively regulates autophagy in
budding yeast and in flies, but it is unclear if the TORC1 pathway
is involved in autophagy repression in these organisms (Berry
and Baehrecke, 2007; Budovskaya et al., 2004).
Autophagy inhibition alone did not trigger apoptosis in mela-
noma cells in vitro, and chloroquine treatment failed to show
antitumor effects in mice fed a control diet in vivo. This is likely
because most cells inside tumors have access to more than
the minimal level of extracellular leucine required for survival.
On the other hand, in animals fed a leucine-free diet, the inhibi-
tion of autophagy likely results in little leucine being liberated
from internal sources so that cellular levels of this essential
amino acid may fall below the threshold needed for survival. To
implement this combination strategy in the current study, we
used chloroquine to inhibit autophagy. However, one caveat of
chloroquine is that as a lysosomotropic compound it may not
only inhibit the autophagic process but also non-autophagy
related functions of lysosomes. Inhibitors to proteins essential
for autophagy, such as the protease, ATG4, and the kinases,
ATG1/ULK1 and VPS34, are likely to be developed in the future.
Using RNAi, we have shown that ATG1 and VPS34 are important(F–H) Cell survival assay.
(I) Immunoblot analyses showing validation of shRNA-mediated knockdowns of
(J) Knockdown of ATG1 mimics effects of expressing Ras-G12V or MEK1-Q56P
(K) Immunoblots show cleavage of caspase-3 and PARP in cells incubated with
(L) Chloroquine (CQ) sensitizes A-2058melanoma cells to partial leucine deprivatio
to leucine concentration in media with or without chloroquine.
(M) Percent survival of A-2058 cells cultured under indicated conditions for 2 days
significantly different from controls.
See also Figure S4.for determining the sensitivity of melanoma cells to leucine
deprivation.
To deprive the melanoma xenografts of leucine, we fed mice
a leucine-free diet that is known to reduce the plasma-leucine
concentration in rodents and humans without greatly affecting
blood insulin levels (Anthony et al., 2004; Guo and Cavener,
2007; Hambraeus et al., 1976). A leucine-free diet is unlikely to
be the ideal approach to deprive tumors of leucine in a clinical
setting. In the future it may be possible to deliver, intravenously,
enzymes that specifically degrade leucine or small molecule
inhibitors of leucine uptake. As a model for the former, asparagi-
nase (L-asparagine amidohydrolase) is an FDA-approved
enzyme that hydrolyzes asparagine to aspartic acid and is
a successful therapy for acute lymphocytic leukemia (ALL).
Enzymes in the leucine catabolic pathway, such as branched
chain aminotransferase (BCAT) (Berg et al., 2007), could be
used in an analogous way if their substrate specificity could be
engineered to be limited to leucine (Conway et al., 2003; Onuffer
and Kirsch, 1995). There appear to be many transporters that
mediate leucine uptake as well (Broer, 2008), and some of the
better-characterized ones, such as LAT1, may be druggable.
Alternatively, the easiest strategy to obtain synergistic effects
with autophagy inhibition and nutrient deprivation on tumor cell
survival may be to coadminister a drug that can deprive tumor
cells of many nutrients, such as an angiogenesis blocker, along
with a specific autophagy inhibitor. Our finding that in the pres-
ence of an autophagy inhibitor, melanoma cells trigger the acti-
vation of caspase-3 when deprived not only of leucine but also of
all essential amino acids, supports the feasibility of this idea.EXPERIMENTAL PROCEDURES
Materials
Reagents were obtained from the following sources: Adriamycin, Rapamycin,
and U-0126 from Calbiochem and LC Laboratories; cell culture grade pure
amino acids, glucose, and chloroquine from Sigma; JC-1 dye from Invitrogen;
immunohistochemistry kits from Vector Laboratories and Dako; cDNA clones
for MEK1, ATG1, and LC3 from Open Biosystems; cDNA clone for H-RAS-
G12V from the Laboratory of Dr. Robert Weinberg (Whitehead Institute);
cDNA clones for BRAF-WT, BRAF-D3, BRAF-V600E, and BRAF-D3-V600E
from Dr. David Tuveson (Cancer Research UK) (Karreth et al., 2009); lentiviral
shRNA constructs from The RNAi Consortium (TRC) (Broad Institute); anti-
bodies to SQSTM1/p62 from American Research Products; antibodies to
ATG1/ULK1, Bcl-xL, caspase-3, cyclin D1, LC3, Melan-A, PARP, phospho-
T202/Y204-ERK, ERK, phopho-T389 S6K1, S6K1, VPS34, as well as HRP-
conjugated anti-mouse, anti-rabbit secondary antibodies from Santa Cruz
Biotechnology Inc., and Cell Signaling Technology.
Cell Lines and Tissue Culture
Cell lineswere obtained from the American Type Culture Collection. Cell culture
mediapowder andserawerepurchased fromthe followingsources:Dulbecco’sATG1.
in sensitizing Mel-ST cells to caspase-3 activation upon leucine deprivation.
decreasing amounts of leucine in the presence or absence of chloroquine.
n. Immunoblots show and graph quantitates activation of caspase-3 in relation
. Data are represented as mean ± SD, and asterisk (*) indicates values that are
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Figure 6. Synergistic Inhibition of Melanoma Tumor Growth in Mice Deprived of Dietary Leucine and Treated with an Autophagy Inhibitor
(A) Photographs of excised tumor xenografts following feeding for 14 days with an isocaloric control diet with added leucine (Control diet), control diet plus
chloroquine (+CQ), leucine-free diet (Leucine diet), or leucine-free diet plus chloroquine (Leucine diet +CQ).
(B) Column scatter dot graph displays the mean ± SEM volume of the tumors. Asterisk (*) indicates volumes that are significantly different from controls. Note that
the tumor that is third from the right in theLeucine diet +CQ group had a flattened disc shape rather than the spherical shape of the large tumors obtained in the
other groups. Thus, it appears deceptively large in the photograph.
(C) In situ TUNEL assay. H+E, representative micrograph images of tumor sections stained with hematoxylin and eosin; TUNEL, representative images of tumor
sections processed in the TUNEL assay; TUNEL+H, representative images of TUNEL results counterstained with hematoxylin. Scale bar, 3 mm.
(D) Representative high-magnification micrographs of tumor sections showing TUNEL-positive, apoptotic regions. Scale bar, 100 mm.
(E) Apoptosis of the melanoma cells inside tumors correlates with the distance from tumor capillaries, and inhibition of autophagy significantly shrinks the viable
cuffs surrounding tumor capillaries. Micrographs show corresponding high and low-magnification images of tumor sections with capillaries indicated (with
arrows) and TUNEL-positive, apoptotic regions. Scale bar, 100 mm.
Cancer Cell
Leucine Deprivation Triggers Melanoma Apoptosis
624 Cancer Cell 19, 613–628, May 17, 2011 ª2011 Elsevier Inc.
Control diet Control diet + CQ -Leucine diet -Leucine diet + CQ
H
+E
TU
NE
L
D
17
5 
cl
ea
ve
d
Ca
sp
as
e-
3
D
17
5 
cl
ea
ve
d 
Ca
sp
as
e-
3 
+ 
bl
oc
kin
g 
pe
pt
id
e
M
el
an
 A
TUNEL D175 cleaved Caspase-3
D175 cleaved Caspase-3
     + blocking peptideB
A
100 μm
100 μm
Figure 7. Combination of Dietary Leucine Deprivation and Autophagy Inhibition Induces Activation of Caspase-3 in Melanoma Tumors
In Vivo
(A) Immunohistochemical analyses showing caspase-3 cleavage in vivo. H+E, images of tumor sections stained with hematoxylin and eosin where capillaries are
denoted with arrows; TUNEL, images of tumor sections processed for the TUNEL assay; D175 cleaved Caspase-3, images of tumor sections stained for active
caspase-3 with the anti-Asp-175 site-specific cleaved caspase-3 antibody; D175 cleaved Caspase-3 + blocking peptide, images of tumor sections stained for
active caspase-3 with the anti-Asp-175 site-specific cleaved caspase-3 antibody that was preincubated with the epitope-blocking peptide; Melan A, images of
tumor sections stained with anti-Melan A, a human melanocyte-specific marker, antibodies. Scale bar, 100 mm.
(B) Representative high-magnification micrographs of tumor tissues showing geographic correlation between the TUNEL-positive signals and the D175 cleaved
caspase-3 positive signals where capillaries are denoted with arrows. Scale bar, 100 mm.
See also Figure S5.
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Leucine Deprivation Triggers Melanoma ApoptosisMEM (DMEM), RPMI-1640, fetal bovine serum (FBS), dialyzed fetal bovine
serum (dFBS), heat-inactivated fetal bovine serum (IFS) from Invitrogen;
amino acid-free, glucose-free RPMI-1640 from US Biological, Inc. Cells were
cultured in the following media: HEK293T cells in DMEM with 10% IFS;
A-2058, SK-MEL-3, SK-MEL-5, SK-MEL-28, Mel-ST, and Mel-ST-derivatives
in DMEM with 10% FBS. For survival assay we treated cells with 20 mM
Q-VD-OPHor100mMZ-VAD-fmkwhendeprivingcells of essential aminoacids.Essential Amino Acid-Deprivation Protocol
To produce cell culture media deficient of single essential amino acids, we re-
constituted the amino acid-free, glucose-free RPMI-1640 media by supple-
menting it with glucose and individual amino acids except the amino acid to
be omitted. Cells were plated in the complete culture media 1 day prior to
the amino acid-deprivation experiments so that the plated cells reached
80% of confluency at the day of experiment. To deprive cells of single aminoCancer Cell 19, 613–628, May 17, 2011 ª2011 Elsevier Inc. 625
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Leucine Deprivation Triggers Melanoma Apoptosisacids, we replaced culture media twice with target amino acid-free RPMI-1640
media and incubated cells until sampling for analysis.
Autophagy Assay Using the DsRed-LC3-GFP Reporter
To develop a dual-color autophagy reporter, we inserted rat LC3 (also known
as ATG8) cDNA in between the cDNAs for DsRed and EGFP so that the DsRed
protein is fused with N terminus of LC3 protein and C terminus of the protein is
connected to EGFP. When indicated, we introduced a deletion of five amino
acids (TALAV) at the ATG4-recognition site near C terminus of LC3 to make
a chimeric protein resistant to ATG4-mediated cleavage. To produce stable
cell lines continuously reporting autophagy activity, recombinant retroviruses
expressing the DsRed-LC3-GFP reporter were generated and used to infect
target cells. The autophagy index is ameasure of the relative change inmedian
fluorescence intensity of GFP to that of DsRed and was calculated with the
formula: autophagy index = 100  (100 3 (FL1/FL2)), where FL1 is Fluores-
cence 1 (the median fluorescence intensity of GFP fluorescence), and FL2 is
Fluorescence 2 (the median fluorescence intensity of DsRed fluorescence).
See Figure S2 for details on the development and validation of the autophagy
reporter.
Flow Cytometric Analyses
Analysis of apoptosis induction using Annexin-V-fluorescein was carried out
according to the assay kit manufacturer’s instructions (Roche). Briefly,
cultured cells were harvested and washed once in PBS, then incubated with
the Ready-to-Use solution of Annexin-V-Fluorescein in a HEPES buffer con-
taining Propidium Iodide. Samples were analyzed using a flow cytometer.
Changes in MOMP were measured using the MOMP-sensitive cationic JC-1
dye according to the supplier’s instruction (Roche). JC-1 exhibits membrane
potential-dependent accumulation in mitochondria, indicated by a fluores-
cence emission shift from green (monomeric form in cytosol) to red (aggre-
gates in mitochondria). Briefly, cultured cells were stained with 2 mM JC-1
for 15 min at the growth condition, washed with PBS, and analyzed using
flow cytometry. When necessary, the concentration of JC-1 was optimized
for different cell types using oligomycin as a control.
Immunofluorescence Assay
Mel-ST and Mel-STMK cells were plated on fibronectin-coated glass cover-
slips in 12-well tissue culture plates. Twenty-four hours later, the slides were
rinsed with PBS once and fixed for 15 min with 4% paraformaldehyde in
PBS warmed to 37C. The slides were rinsed twice with PBS, and cells were
permeabilized with 0.05% Triton X-100 in PBS for 5 min. After rinsing twice
with PBS, the slides were incubated with primary antibodies for 2 hr at room
temperature, rinsed four times with PBS, and incubated with secondary anti-
bodies (1:400 in 5% normal donkey serum) for 1 hr at room temperature in
the dark, washed four times with PBS. Slides were finally mounted on glass
coverslips using VECTASHIELD (Vector Laboratories), and images were
collected and analyzed on a PerkinElmer spinning disk confocal microscopy
system.
Human Xenograft Tumor Model and Dietary Leucine Deprivation
Immunodeficient mice (NCR nude, nu/nu; Taconic Laboratories) were main-
tained in a pathogen-free facility and were given autoclaved food and water
ad libitum, if not otherwise specified. A-2058 melanoma cells were xeno-
grafted into 6-week-old immunodeficient mice. Briefly, 1 3 106 melanoma
cells were resuspended in 200 ml of media and injected subcutaneously in
the upper flank region of mice that had been anesthetized with isoflurane.
Tumors were allowed to grow to 100 mm3 in size, and the mice were then
initiated on the dietary leucine restriction using an isocaloric leucine-free,
synthetic diet alone or along with chloroquine treatment. Both the isocaloric
control diet with added leucine and the leucine-free synthetic diet were ob-
tained from Research Diet, Inc. Based on a series of preliminary experiments,
chloroquine was injected intraperitoneally at 60 mg/kg body weight two times
perweek. Tumor volumeswere estimatedwith the formula: volume= (2a3 b)/2,
where a = shortest and b = longest tumor lengths, respectively, in millimeters.
When necessary, animals were sacrificed, and tumors were harvested and
analyzed using standard histology and immunohistochemistry methods.
Animal research protocols were approved by the MIT Committee on Animal
Care, and all experiments were performed according to the official guidelines626 Cancer Cell 19, 613–628, May 17, 2011 ª2011 Elsevier Inc.of the MIT Committee on Animal Care and the American Association of Labo-
ratory Animal Care.
Lentiviral shRNA-Mediated RNAi
For the gene knockdown experiments, we obtained lentiviral shRNA
constructs from TRC at the Broad Institute and produced recombinant lentivi-
ruses using a transient transfection protocol. Briefly, we transfected HEK293T
cells with the lentiviral shRNA plasmids and the packaging plasmids
(pdeltaVPR and pVSVG) according to TRC standard protocols and used lenti-
viral supernatants to infect target cells (Moffat et al., 2006).
Statistical Analyses
Experimental results were analyzed with a Student’s t test and graphed using
Prism software (GraphPad Software, Inc.). In vitro data are expressed as
mean ± SD and in vivo data as mean ± SEM. A p value <0.05 was considered
statistically significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and five figures and can be found with this article online at doi:10.1016/j.ccr.
2011.03.012.
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